Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy comprising treatment-resistant adult and pediatric focal seizures, rare and pediatric forms of epilepsy, and other neurological disorders; and XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of epilepsy. The company also develops GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN007, a central nervous system (CNS)-acting calcium channel blocker that directly modulates Cav2.1, which is a critical calcium channel implicated in the pathophysiology of hemiplegic migraine, a rare and debilitating neurological disorder. Xenon Pharmaceuticals Inc. has collaboration agreements with Genentech, Inc. and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300
Debt
Debt-to-Equity Ratio0.82
Current Ratio9.70
Quick Ratio9.70
Price-To-Earnings
Trailing P/E Ratio-5.93
Forward P/E Ratio-6.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$310,000.00
Price / Sales466.24
Cash FlowN/A
Price / CashN/A
Book Value$2.00 per share
Price / Book5.10
Profitability
EPS (Most Recent Fiscal Year)($1.72)
Net Income$-30,700,000.00
Net Margins-9,872.67%
Return on Equity-79.04%
Return on Assets-58.43%
Miscellaneous
Employees81
Outstanding Shares14,170,000
Market Cap$142.43
Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc (NASDAQ:XENE) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.27. Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 79.04%. View Xenon Pharmaceuticals' Earnings History.
When is Xenon Pharmaceuticals' next earnings date?
What price target have analysts set for XENE?
2 Wall Street analysts have issued 1 year price objectives for Xenon Pharmaceuticals' stock. Their predictions range from $6.00 to $9.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $7.50 in the next twelve months. This suggests that the stock has a possible downside of 26.5%. View Analyst Ratings for Xenon Pharmaceuticals.
What is the consensus analysts' recommendation for Xenon Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include CannTrust (CNTTF), Beyondspring (BYSI), Merus (MRUS), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Depomed (DEPO), Arcus Biosciences (RCUS), Evolus (EOLS), ArQule (ARQL), Stemline Therapeutics (STML), Lannett (LCI), Magenta Therapeutics (MGTA), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK) and ZEALAND PHARMA/S (ZEAL).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Dr. Simon N. Pimstone, CEO & Director (Age 50)
- Mr. Ian C. Mortimer, Pres, CFO, COO & Company Sec. (Age 42)
- Mr. Robin P. Sherrington, Exec. VP of Bus. & Corp. Devel. (Age 57)
- Dr. James R. Empfield, Sr. VP of Drug Discovery of Xenon Pharmaceuticals USA Inc (Age 57)
- Ms. Jodi Regts B.A., MBA, VP of Corp. Affairs & Investor Relations
Has Xenon Pharmaceuticals been receiving favorable news coverage?
Media headlines about XENE stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Xenon Pharmaceuticals earned a media sentiment score of 0.05 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 43.41 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Xenon Pharmaceuticals?
Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of XENE stock can currently be purchased for approximately $10.20.
How big of a company is Xenon Pharmaceuticals?
Xenon Pharmaceuticals has a market capitalization of $142.43 million and generates $310,000.00 in revenue each year. The biopharmaceutical company earns $-30,700,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Xenon Pharmaceuticals employs 81 workers across the globe.
How can I contact Xenon Pharmaceuticals?
Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)
MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe XENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
